Generic substitutions raise growing concerns among ophthalmologists
While the generic drug market steadily grows in Europe, and generic substitution has become the rule in all countries, concern exists among ophthalmologists about tolerance and efficacy, as well as their power to to maintain proper control of a patient’s treatment.
“The problem in ophthalmology is that bioequivalence cannot be tested. Therefore, if patients ask me whether a generic I prescribe is equivalent to the brand, I cannot answer,” Jean-Philippe Nordmann, MD, said in the cover story of Ocular Surgery News: Europe Edition’s latest issue.
In addition, due to the variety of generic drugs available, patients may be given different products in different pharmacies, and the choice is in the hands of pharmacists rather than the prescriber.